A Double-Blind, Randomised, Placebo-Controlled, Multicentre, Relapse-Prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder.
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2016
At a glance
- Drugs Vortioxetine (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- 03 Feb 2016 Results published in Lundbeck A/S media release.
- 17 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
- 03 Jul 2012 Planned number of patients changed from 300 to 600 as reported by EudraCT.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History